VCEL
Vericel Corp
NASDAQ · Healthcare · Biotechnology · US
$40.02
−0.02%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- $0.02
- Revenue estimate
- $78.2M
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- $0.04
- EPS estimate
- -$0.03
- Revenue actual
- $77.5M
- Revenue estimate
- $72.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +214.4%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $63
- PT range
- $58 – $72
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 30, 2026 | -$0.03 | $0.04 | Beat 238.22% | $77.5M |
| May 7, 2026 | -$0.15 | -$0.12 | Beat 20.00% | $68.4M |
| Feb 26, 2026 | $0.45 | $0.45 | Miss -0.80% | $92.9M |
| Nov 6, 2025 | -$0.02 | $0.10 | Beat 600.00% | $67.5M |
| Jul 31, 2025 | -$0.04 | -$0.01 | Beat 75.00% | $63.2M |
| May 8, 2025 | -$0.09 | -$0.23 | Miss -155.56% | $52.6M |
| Feb 27, 2025 | $0.31 | $0.38 | Beat 22.58% | $75.4M |
| Nov 7, 2024 | -$0.05 | -$0.02 | Beat 60.00% | $57.9M |
| Aug 1, 2024 | -$0.10 | -$0.10 | In line | $52.7M |
| Feb 29, 2024 | $0.17 | $0.26 | Beat 52.94% | $65.0M |
| Aug 2, 2023 | -$0.13 | -$0.11 | Beat 15.38% | $45.9M |
| Feb 23, 2023 | $0.04 | $0.12 | Beat 238.98% | $52.7M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026